Veracyte to Host Conference Call and Webcast to Discuss First Quarter 2016 Financial Results on Thursday, May 5, 2016

SOUTH SAN FRANCISCO, Calif., April 19, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced that it will report its first quarter 2016 financial results after close of market on Thursday, May 5, 2016. Following the announcement, Veracyte's management will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the company's financial results and business progress.

The live webcast and subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com. Alternatively, please call (855) 541-0980 (U.S.) or (970) 315-0440 (international) to listen to the live conference call. The conference ID number is 93546799. The webcast replay will be available on the company's website approximately two hours following completion of the call and archived on the company's website for 90 days following the presentation.

About Veracyte

Veracyte (NASDAQ: VCYT) is pioneering the field of molecular cytology, offering genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte's Afirma Thyroid FNA Analysis centers on the proprietary Afirma Gene Expression Classifier (GEC) and is becoming a new standard of care in thyroid nodule assessment. The Afirma test is recommended in leading practice guidelines and is covered for nearly 180 million lives in the United States, including through Medicare and many commercial insurance plans. Veracyte is expanding its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. In April 2015, the company launched the Percepta Bronchial Genomic Classifier, a test to evaluate patients with lung nodules that are suspicious for cancer. Veracyte is developing a second product in pulmonology, targeting interstitial lung diseases, including idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.

Veracyte, Afirma, Percepta, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc.

SOURCE Veracyte

Related Links

http://www.veracyte.com